Correction to: npj Breast Cancer, published online 08 September 2023 In this article, the funding from Roche was inadvertently omitted. Additionally, in the Acknowledgements, the affiliation for Paola Tagliabue was incorrectly provided as ‘Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy’ and has been corrected to ‘Vimercate Hospital, ASST della Brianza, Vimercate, Italy’. The original article has been corrected.
Fabi A., Carbognin L., Botticelli A., Paris I., Fuso P., Savastano M.C., et al. (2023). Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer (npj Breast Cancer. NPJ BREAST CANCER, 9(1) [10.1038/s41523-023-00596-1].
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer (npj Breast Cancer
Valerio M. R.;Fontana A.;
2023-01-01
Abstract
Correction to: npj Breast Cancer, published online 08 September 2023 In this article, the funding from Roche was inadvertently omitted. Additionally, in the Acknowledgements, the affiliation for Paola Tagliabue was incorrectly provided as ‘Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy’ and has been corrected to ‘Vimercate Hospital, ASST della Brianza, Vimercate, Italy’. The original article has been corrected.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Author Correction Real-world ANASTASE study - 2023.pdf
accesso aperto
Tipologia:
Versione Editoriale
Dimensione
379.54 kB
Formato
Adobe PDF
|
379.54 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
